Outcomes in older adults with acute lymphoblastic leukaemia (ALL): Results from the international MRC UKALL XII/ECOG2993 trial

British Journal of Haematology

Volumn 157, Issue 4, 2012, Pages 463-471

  Sive, Jonathan I ^a   Buck, Georgina ^b   Fielding, Adele ^c   Lazarus, Hillard M ^d   Litzow, Mark R ^e   Luger, Selina ^f   Marks, David I ^g   Mcmillan, Andrew ^h   Moorman, Anthony V ⁱ   Richards, Susan M ^b   Rowe, Jacob M ^j   Tallman, Martin S ^k   Goldstone, Anthony H ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^h NOTTINGHAM CITY HOSPITAL   (United Kingdom)

ⁱ NEWCASTLE UNIVERSITY   (United Kingdom)

^j TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Acute lymphoblastic leukaemia; Chemotherapy; Elderly; Infection

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOGRAFT; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENETIC RISK; HUMAN; INFECTION RATE; LEUKEMIA REMISSION; LIVER TOXICITY; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; VIRUS INFECTION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; INFECTION; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860012521     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09095.x     Document Type: Article

References (29)

1. Annino, L., Vegna, M.L., Camera, A., Specchia, G., Visani, G., Fioritoni, G., Ferrara, F., Peta, A., Ciolli, S., Deplano, W., Fabbiano, F., Sica, S., Di Raimondo, F., Cascavilla, N., Tabilio, A., Leoni, P., Invernizzi, R., Baccarani, M., Rotoli, B., Amadori, S. & Mandelli, F. for the GIMEMA Group (2002) Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood, 99, 863-871.
2. Appelbaum, F.R. (2005) Impact of age on the biology of acute leukemia. In: American Society of Clinical Oncology Educational Book (ed. by M.C. Perry), pp. 528-532.
3. DeAngelo, D.J., Yu, D., Johnson, J.L., Coutre, S.E., Stone, R.M., Stopeck, A.T., Gockerman, J.P., Mitchell, B.S., Appelbaum, F.R. & Larson, R.A. (2007) Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood, 109, 5136-5142.
4. Fielding, A.F., Buck, G., Lazarus, H.M., Litzow, M.R., Luger, S., Marks, D.I., McMillan, A., Moorman, A.V., Paietta, E., Richards, S.M., Tallman, M.S., Rowe, J.M. & Goldstone, A.H. (2010) Imatinib significantly enhances long-term outcomes in philadelphia positive acute lymphoblastic leukaemia; final results of the UKALLXII/ECOG2993 Trial. Blood (ASH Annual Meeting Abstracts), 116, 169.
5. Gardner, A., Mattiuzzi, G. & Faderl, S. (2008) Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. Journal of Clinical Oncology, 26, 5684-5688.
6. Goekbuget, N., Leguay, T., Hunault M., Chadi Al-Nawakil, C., Chevallier, P., Dombret, H., Fritsch, G., Oriol, A., Ribera, J.M., Rousselot, P., Sancho, J.M. & Hoelzer, D. (2008) First European chemotherapy schedule for elderly patients with acute lymphoblastic leukemia: promising remission rate and feasible moderate dose intensity consolidation. Blood (ASH Annual Meeting Abstracts), 112, 304.
7. Gökbuget, N., Hoelzer, D., Arnold, R., Böhme, A., Bartram, C.R., Freund, M., Ganser, A., Kneba, M., Langer, W., Lipp, T., Ludwig, W.D., Maschmeyer, G., Rieder, H., Thiel, E., Weiss, A. & Messerer, D. (2000) Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematology/oncology Clinics of North America, 14, 1307-1325.
8. Goldstone, A.H., Richards, S.M., Lazarus, H.M., Tallman, M.S., Buck, G., Fielding, A.K., Burnett, A.K., Chopra, R., Wiernik, P.H., Foroni, L., Paietta, E., Litzow, M.R., Marks, D.I., Durrant, J., McMillan, A., Franklin, I.M., Luger, S., Ciobanu, N. & Rowe, J.M. (2008) In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111, 1827-1833.
9. Groupe Français de Cytogénétique Hématologique (1996) Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. Blood, 87, 3135-3142.
10. Huguet, F., Leguay, T., Raffoux, E., Thomas, X., Beldjord, K., Delabesse, E., Chevallier, P., Buzyn, A., Delannoy, A., Chalandon, Y., Vernant, J.P., Lafage-Pochitaloff, M., Chassevent, A., Lhéritier, V., Macintyre, E., Béné, M.C., Ifrah, N. & Dombret, H. (2009) Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. Journal of Clinical Oncology, 27, 911-918.
11. Kantarjian, H.M., O'Brien, S., Smith, T.L., Cortes, J., Giles, F.J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., Ha, C.S., Keating, M.J., Murphy, S. & Freireich, E.J. (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, for adult acute lymphoblastic leukemia. Journal of Clinical Oncology, 18, 547-561.
12. Larson, R.A. (2005) Acute lymphoblastic leukemia: older patients and newer drugs. Hematology American Society of Hematology. Education Program, 2005, 131-136.
13. Moorman, A.V., Harrison, C.J., Buck, G.A., Richards, S.M., Secker-Walker, L.M., Martineau, M., Vance, G.H., Cherry, A.M., Higgins, R.R., Fielding, A.K., Foroni, L., Paietta, E., Tallman, M.S., Litzow, M.R., Wiernik, P.H., Rowe, J.M., Goldstone, A.H., Dewald, G.W. & on behalf of the Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute (2007) Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood, 109, 3189-3197.
14. Moorman, A.V., Chilton, L., Wilkinson, J., Ensor, H.M., Bown, N. & Proctor, S.J. (2010) A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood, 115, 206-214.
15. O'Brien, S., Thomas, D.A., Ravandi, F., Faderl, S., Pierce, S. & Kantarjian, H. (2008) Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer, 113, 2097-2101.
16. Pagano, L., Mele, L., Trapè, G. & Leone, G. (2004) The treatment of acute lymphoblastic leukaemia in the elderly. Leukaemia & Lymphoma, 45, 117-123.
17. Petersdorf, S.H., Kopecky, K.J., Head, D.R., Boldt, D.H., Balcerzak, S.P., Wun, T., Roy, V., Veith, R.W. & Appelbaum, F.R. (2001) Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia, 15, 208-216.
18. Pullarkat, V., Slovak, M.L., Kopecky, K.J., Forman, S.J. & Appelbaum, F.R. (2008) Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood, 111, 2563-2572.
19. Pulte, D., Gondos, A. & Brenner, H. (2009) Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood, 113, 1408-1411.
20. Robak, T., Szmigielska-Kapłon, A., Wrzesień-Kuś, A., Wierzbowska, A., Skotnicki, A.B., Piatkowska-Jakubas, B., Kuliczkowski, K., Mazur, G., Zduńczyk, A., Stella-Hołowiecka, B., Hołowiecki, J., Dwilewicz-Trojaczek, J., Madry, K., Dmoszyńska, A. & Cioch, M. (2004) Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group experience. Annals of Hematology, 83, 225-231.
21. Rousselot, P., Cayuela, J.M., Hayette, S., Récher, C., Leguay, T., Salanoubat, C., Witz, F., Alexis, M., Hunault, M., Janvier, M., Agape, P., Berthou, C., Jourdan, E., Fernandes, J., Sutton, L., Banos, A., Reman, O., Lioure, B., Thomas, X., Ifrah, N., Gokbuget, N., Hoelzer, D., Delannoy, A., Bassan, R., Ribera, J.M., Giebel, S., Dombret, H. & Ottmann, O.G. (2010) Dasatinib and low intensity chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL (EWALL-PH-01): kinetic of response, resistance and prognostic significance. Blood (ASH Annual Meeting Abstracts), 116, 172.
22. Rowe, J.M., Buck, G., Burnett, A.K., Chopra, R., Wiernik, P.H., Richards, S.M., Lazarus, H.M., Franklin, I.M., Litzow, M.R., Ciobanu, N., Prentice, H.G., Durrant, J., Tallman, M.S., Goldstone, A.H. & for ECOG and the MRC/NCRI Adult Leukemia Working Party (2005) Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood, 106, 3760-3767.
23. Rytting, M. (2010) Peg-asparaginase for acute lymphoblastic leukemia. Expert Opinion on Biological Therapy, 10, 833-839.
24. Sancho, J.M., Ribera, J.M., Xicoy, B., Morgades, M., Oriol, A., Tormo, M., del Potro, E., Debén, G., Abella, E., Bethencourt, C., Ortín, X., Brunet, S., Ortega-Rivas, F., Novo, A., López, R., Hernández-Rivas, J.M., Sanz, M.A., Feliu, E. & on behalf of the PETHEMA Group (2007) Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. European Journal of Haematology, 78, 102-110.
25. Taylor, P.R., Reid, M.M., Bown, N., Hamilton, P.J. & Proctor, S.J. (1992) Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome. Blood, 80, 1813-1817.
26. Thomas, X., Olteanu, N., Charrin, C., Lhéritier, V., Magaud, J.P. & Fiere, D. (2001) Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. American Journal of Hematology, 67, 73-83.
27. Thomas, D.A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Ravandi, F., Verstovsek, S., Jorgensen, J.L., Bueso-Ramos, C., Andreeff, M., Pierce, S., Garris, R., Keating, M.J., Cortes, J. & Kantarjian, H.M. (2010) Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. Journal of Clinical Oncology, 28, 3880-3889.
28. Topp, M.S., Kufer, P. & Gökbuget, N. (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. Journal of Clinical Oncology, 29, 2493-2498.
29. Wetzler, M., Dodge, R.K., Mrózek, K., Carroll, A.J., Tantravahi, R., Block, A.W., Pettenati, M.J., Le Beau, M.M., Frankel, S.R., Stewart, C.C., Szatrowski, T.P., Schiffer, C.A., Larson, R.A. & Bloomfield, C.D. (1999) Prospective karyotype analysis in adult acute lymphoblastic Leukemia. The Cancer and Leukemia Group B experience. Blood, 93, 3983-3993.